TY - JOUR
T1 - Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases
T2 - Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study
AU - Marty, Michel
AU - Sersa, Gregor
AU - Garbay, Jean Rémi
AU - Gehl, Julie
AU - Collins, Christopher G.
AU - Snoj, Marko
AU - Billard, Valérie
AU - Geertsen, Poul F.
AU - Larkin, John O.
AU - Miklavcic, Damijan
AU - Pavlovic, Ivan
AU - Paulin-Kosir, Snezna M.
AU - Cemazar, Maja
AU - Morsli, Nassim
AU - Soden, Declan M.
AU - Rudolf, Zvonimir
AU - Robert, Caroline
AU - O'Sullivan, Gerald C.
AU - Mir, Lluis M.
N1 - Funding Information:
We greatly acknowledge the contribution of our ESOPE colleagues Claire Bernat, Dr. Caroline Robert, Dr. Salim Laghouati, Dr. Olivier Tembo, Dr. Janja Ocvirk, Dr. Martina Rebersek, Dr. Franc Pompe, Breda Slekovec Kolar, Dr. Simona Kranjc, Susanne Wehmeyer, Ingrid Krøyer Kaiser, Ingelise Jæger, Dr. Naima Bedaı¨ria, Dr. Ruggero Cadossi, Dr. Francesca de Terlizzi, Dr. Gianluca Selvaggi, Claire Cronin and Dr. Colum Dunne. The research was funded by the EU commission within the 5th FP – Quality of Life and Management of Living Resources Programme, project ESOPE (QLK-2002-02003), and by national research grants to the ESOPE partners.
PY - 2006/11/1
Y1 - 2006/11/1
N2 - Purpose: To evaluate and confirm efficacy and safety of electrochemotherapy with bleomycin or cisplatin on cutaneous and subcutaneous tumour nodules of patients with malignant melanoma and other malignancies in a multicenter study. Patients and methods: This was a two year long prospective non-randomised study on 41 patients evaluable for response to treatment and 61 evaluable for toxicity. Four cancer centers enrolled patients with progressive cutaneous and subcutaneous metastases of any histologically proven cancer. The skin lesions were treated by electrochemotherapy, using application of electric pulses to the tumours for increased bleomycin or cisplatin delivery into tumour cells. The treatment was performed using intravenous or intratumoural drug injection, followed by application of electric pulses generated by a Cliniporator™ using plate or needle electrodes. Tumour response to electrochemotherapy as well as possible side-effects with respect to the treatment approach, tumour histology and location of the tumour nodules and electrode type were evaluated. Results: An objective response rate of 85% (73.7% complete response rate) was achieved on the electrochemotherapy treated tumour nodules, regardless of tumour histology, and drug used or route of its administration. At 150 days after the treatment (median follow up was 133 days and range 60-380 days) local tumour control rate for electrochemotherapy was 88% with bleomycin given intravenously, 73% with bleomycin given intratumourally and 75% with cisplatin given intratumourally, demonstrating that all three approaches were similarly effective in local tumour treatment. Furthermore, electrochemotherapy was equally effective regardless of the tumour type and size of the nodules treated. Side-effects of electrochemotherapy were minor and acceptable, as reported by the patients. Conclusion: We demonstrated that electrochemotherapy is an easy, highly effective, safe and cost-effective approach for the treatment of cutaneous and subcutaneous tumour nodules of different malignancies. Electrochemotherapy can provide immediate clinical benefit in patients with advanced cutaneous and subcutaneous metastases.
AB - Purpose: To evaluate and confirm efficacy and safety of electrochemotherapy with bleomycin or cisplatin on cutaneous and subcutaneous tumour nodules of patients with malignant melanoma and other malignancies in a multicenter study. Patients and methods: This was a two year long prospective non-randomised study on 41 patients evaluable for response to treatment and 61 evaluable for toxicity. Four cancer centers enrolled patients with progressive cutaneous and subcutaneous metastases of any histologically proven cancer. The skin lesions were treated by electrochemotherapy, using application of electric pulses to the tumours for increased bleomycin or cisplatin delivery into tumour cells. The treatment was performed using intravenous or intratumoural drug injection, followed by application of electric pulses generated by a Cliniporator™ using plate or needle electrodes. Tumour response to electrochemotherapy as well as possible side-effects with respect to the treatment approach, tumour histology and location of the tumour nodules and electrode type were evaluated. Results: An objective response rate of 85% (73.7% complete response rate) was achieved on the electrochemotherapy treated tumour nodules, regardless of tumour histology, and drug used or route of its administration. At 150 days after the treatment (median follow up was 133 days and range 60-380 days) local tumour control rate for electrochemotherapy was 88% with bleomycin given intravenously, 73% with bleomycin given intratumourally and 75% with cisplatin given intratumourally, demonstrating that all three approaches were similarly effective in local tumour treatment. Furthermore, electrochemotherapy was equally effective regardless of the tumour type and size of the nodules treated. Side-effects of electrochemotherapy were minor and acceptable, as reported by the patients. Conclusion: We demonstrated that electrochemotherapy is an easy, highly effective, safe and cost-effective approach for the treatment of cutaneous and subcutaneous tumour nodules of different malignancies. Electrochemotherapy can provide immediate clinical benefit in patients with advanced cutaneous and subcutaneous metastases.
KW - Bleomycin
KW - Cisplatin
KW - Complete response
KW - Cutaneous metastases
KW - Electric pulses
KW - Electrochemotherapy
KW - Melanoma
KW - Recurrent breast cancer
UR - http://www.scopus.com/inward/record.url?scp=33751035728&partnerID=8YFLogxK
U2 - 10.1016/j.ejcsup.2006.08.002
DO - 10.1016/j.ejcsup.2006.08.002
M3 - Article
AN - SCOPUS:33751035728
SN - 1359-6349
VL - 4
SP - 3
EP - 13
JO - European Journal of Cancer, Supplement
JF - European Journal of Cancer, Supplement
IS - 11
ER -